Survodutide (10 mg Vial) Dosage Protocol
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist under development for obesity and metabolic liver disease. Phase 2 trials showed 12.5–14.9% weight loss vs placebo over 46 weeks with weekly subcutaneous dosing.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
Standard / Gradual Titration (2 mL = 5 mg/mL)
Route & Frequency: Subcutaneous injection once weekly (all clinical trials used weekly dosing).
| Week | Weekly Dose (mg) | Weekly Dose (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 0.6 mg | 600 mcg | 12 units (0.12 mL) |
| Weeks 3–4 | 1.2 mg | 1200 mcg | 24 units (0.24 mL) |
| Weeks 5–6 | 1.8 mg | 1800 mcg | 36 units (0.36 mL) |
| Weeks 7–8 | 2.4 mg | 2400 mcg | 48 units (0.48 mL) |
| Weeks 9–10 | 3.6 mg | 3600 mcg | 72 units (0.72 mL) |
| Weeks 11–12 | 4.8 mg | 4800 mcg | 96 units (0.96 mL) |
| Week 13+ | 6.0 mg | 6000 mcg | 120 units (1.20 mL)* |
*Note: The 6.0 mg maintenance dose (120 units / 1.20 mL) exceeds a standard 100‑unit (1 mL) insulin syringe. Use a 1 mL or 3 mL Luer‑lock syringe with appropriate needle, or administer as two separate injections.
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week weekly protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (Survodutide, 10 mg each) | 8 weeks ≈ 2 vials (~17 mg total) 12 weeks ≈ 4 vials (~39 mg total) 16 weeks ≈ 7 vials (~63 mg total) |
| Insulin Syringes (U‑100) or 1 mL Luer‑lock Syringes | Per week: 1 syringe (once weekly) 8 weeks: 8 syringes 12 weeks: 12 syringes 16 weeks: 16 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle 12 weeks (4 vials): 8 mL → 1 × 10 mL bottle 16 weeks (7 vials): 14 mL → 2 × 10 mL bottles |
| Alcohol Swabs | Per week: 2 swabs 8 weeks: 16 swabs 12 weeks: 24 swabs 16 weeks: 32 swabs → recommend 1 × 100‑count box |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component enhances satiety and glycemic control, while the glucagon component increases energy expenditure and promotes hepatic lipid oxidation, providing additive effects on body weight and liver fat beyond GLP-1 alone.
Potential Benefits & Side Effects
Potential Benefits
- Phase 2 weight loss of 12.5–14.9% vs placebo over 46 weeks.
- Improved liver enzyme markers in NAFLD/NASH populations.
- Consistent efficacy across multiple randomized controlled trials.
Side Effect Profile
- GI effects: nausea, vomiting, diarrhea, constipation (most common during escalation).
- Gradual titration mitigates GI tolerability.
Lifestyle Factors
- Protein-forward diet to preserve lean mass.
- Combine resistance + aerobic training.
- Stay hydrated, especially during GI side effects.
Injection Technique
- Subcutaneous, once weekly.
- For 6 mg dose (>100 units), use 1 mL Luer-lock syringe or split into 2 injections.